Chitosan Hemostat Patents: Top Companies & Filing Trends 2026
- 55.6% of all 198 records sit with just five assignees, and 85.4% with ten — this is a field with a narrow set of gatekeepers, not a fragmented one.
- Sterilising and disinfecting claims (A61L) touch 78.3% of records while polysaccharide-specific chemistry (C08B) appears in only 8.6% — most filers claim the dressing's antimicrobial function, few claim the underlying polymer science.
- Filing peaked in 2018 at 35 records and the 2021→2024 window still shows +50% growth, so the category is not in decline even as recent years understate themselves due to publication lag.
Filing growth compares 2021 (2 records) with 2024 (3) — a three-year span. 2024 is the most recent year we treat as complete: publication lags filing by roughly 18 months, so 2025 onwards are still filling in and any growth rate that ends there would understate the field. Top-5 share is the combined record count of the five largest assignees divided by all 198 records in scope (CR5), not by the ranked leaders only.
What this landscape covers
This landscape tracks patent activity where chitosan hemostat, polysaccharide hemostat or chitosan dressing claims intersect with functional properties such as degree of deacetylation, mucoadhesion, antibacterial effect, blood absorption, wound removal, or sterilization effect. The scope spans 2015 through the 2026 data cut-off, capturing 198 published records that form the basis of the assignee ranking, technology composition and filing trend shown below.
Because publication lags filing by roughly 18 months, the most recent one to two years in any trend chart will always look thinner than they eventually turn out to be. Patent families, not raw document counts, are the fairer unit for judging real filing activity — this is the unit used throughout the assignee ranking on this page.
Filing trend and technology composition
Two views of the same 198 records: how filing activity has moved year over year, and which IPC subclasses the claims actually sit in.
Filing trend, 2017–2026
Filings rose from 7 in 2017 to a peak of 35 in 2018, and the 2021-to-2024 span — the last window unaffected by publication lag — shows growth from 2 to 3 records, a +50% increase. Years after 2024 are still filling in and should not be read as a slowdown.
IPC subclass composition
A61L (sterilising and disinfecting) appears in 78.3% of the 198 records, far ahead of A61F implants (31.8%) and A61K medicinal preparations (31.3%). Polysaccharide-specific chemistry under C08B sits at just 8.6%, and polymer processing under C08J at 9.1% — the two branches closest to the raw material science, rather than the finished dressing, are the least claimed.
Shares are the percentage of the 198 records in scope. A patent can carry several IPC classes, so the shares add up to more than 100%.
Go deeper on Chitosan and Polysaccharide Hemostats with Eureka
This page is one run against one query. Ask Eureka your own question about chitosan and polysaccharide hemostats and every answer comes back with the patent numbers behind it.
Try EurekaRepresentative filing and most-cited prior art
US20210052766A1 — Chitosan dressing for control of gastrointestinal bleeding
The present invention relates to a biocompatible, foldable, thin profile, low mass and high surface area, chitosan dressing, optionally modified with catechol, and suitable for treating bleeding in a physiological environment, e.g. gastrointestinal tract. The characteristics and structures of the chitosan dressing are provided. Methods of making and using the chitosan dressing are also provided.Filed by Tricol Biomedical, Inc., published 2021-02-25.
| # | Publication no. | Patent title | Citations |
|---|---|---|---|
| 1 | US20090130186A1 | Wound dressing assemblies, systems, and methods formed from hydrophilic polymer sponge structures such as chi… | 82 |
| 2 | US20090018479A1 | Absorbable tissue dressing assemblies, systems, and methods formed from hydrophilic polymer sponge structures… | 80 |
| 3 | US8269058B2 | Absorbable tissue dressing assemblies, systems, and methods formed from hydrophilic polymer sponge structures… | 64 |
| 4 | US20140046236A1 | Chitosan biomimetic scaffolds and methods for preparing the same | 53 |
| 5 | WO2009011856A1 | Absorbable tissue dressing assemblies, systems, and methods formed from hydrophilic polymer sponge structures… | 51 |
| 6 | US9205170B2 | Wound dressing devices and methods | 42 |
| 7 | US20180214160A1 | Percutaneous vascular injury treatment systems and methods | 37 |
| 8 | US20220218878A1 | Controlled heat delivery compositions | 36 |
| 9 | US20100172958A1 | Wound dressing devices and methods | 28 |
| 10 | WO2015123778A1 | Freeze-dried polymer compositions for mixing with platelet rich plasma to form implants for tissue repair and… | 25 |
Citation counts favour older filings inside any searched corpus — treat them as a signal of influence on the field, not of current commercial relevance.
Each row carries its publication number; clicking a row searches Eureka by that number.
Put your own technology through the same analysis
Eureka on the web
When you want the answer in the next five minutes.
The agent works the prompt against patents and technical literature, citing every source.
Run your analysis now →MCP server & REST API
When it has to run inside your own pipeline.
Patent search, landscape analysis and assignee resolution as MCP tools. Drop them into any agent framework, or call REST directly.
Browse MCP servers →What the data means for strategy
Three patterns worth acting on before drafting new claims or scoping freedom-to-operate.
The field has a narrow gatekeeper set
Five assignees hold 110 of the 198 records in scope, and ten hold 169. That is a steep concentration curve for a biomaterials category — most of the remaining 56 ranked companies hold only a handful of filings each, forming a long tail rather than a second tier of scale.
Claims cluster on function, not on the polymer itself
Sterilising and disinfecting claims under A61L cover 78.3% of records, while claims specific to polysaccharide chemistry under C08B cover only 8.6%. Most filers are protecting what the dressing does to a wound, not the underlying carbohydrate science that makes it work.
Activity is rebuilding after the 2018 peak
Filings peaked at 35 in 2018 and cooled afterward, but the 2021-to-2024 window — the last stretch not distorted by publication lag — shows a +50% increase from 2 to 3 records. That is a modest base, but it points to renewed rather than declining interest.
Eureka can read the same corpus for gaps instead of for coverage: under-claimed branches adjacent to chitosan and polysaccharide hemostats, with the prior art for and against each one.
Who holds the claim space
The leader holds 37 records; fifth place holds 14; tenth place holds 9 — a steep drop from the top before the field flattens into single-digit filers.
One filer sits well ahead of the field
The top-ranked assignee's 37 records is more than double the fifth-place holder's 14, establishing a clear scale gap at the top of the ranking rather than a cluster of similarly sized competitors.
University-hospital pairings dominate co-filing
The strongest co-assignee pairs link university and medical-centre entities, with the top pairing appearing together 15 times. This suggests the densest claim clusters come out of academic-clinical collaborations rather than corporate R&D alone.
Even the leaders show no recent-year filings yet
Every one of the assignees with the strongest historical or co-filing position shows zero records in the latest year. Given the 18-month publication lag, this reflects incomplete data for recent filings rather than an actual stop in R&D activity.
| Assignee | Recent year | YoY |
|---|---|---|
| Tricol Biomedical, Inc. | 0 | — |
| Loma Linda University Medical Center | 0 | — |
| North Carolina State University | 0 | — |
| Foshan United Medical Technology Co., Ltd. | 0 | — |
| ORTHO REGENERATIVE TECH | 0 | — |
| Loma Linda University | 0 | — |
| ADVAMEDICA INC | 0 | — |
| Marine Essence Biosciences Corporation of USA | 0 | — |
Where to take this analysis
The landscape points to three practical next steps for teams working in this space.
Run a freedom-to-operate check on sterilising claims
With 78.3% of records touching A61L, any new dressing formulation is likely to cross existing sterilising or disinfecting claims held by the top assignees. A targeted FTO search against the leading five filers is the fastest way to see what is actually blocked.
Explore FTO workflows in EurekaScope claims around under-claimed polysaccharide chemistry
C08B and C08J together sit well below the core sterilising and implant classes, which points to open claim space around the raw polymer chemistry rather than the finished-dressing function.
Draft a claim map in EurekaTrack the leading assignees for renewed filing activity
Recent-year momentum shows zero filings across the top assignees, which is consistent with publication lag rather than a real pause. Monitoring these entities as 2025-and-later data fills in will show whether the +50% growth trend continues.
Set up assignee monitoring in EurekaCommon questions on this landscape
The ranking in this dataset covers 66 assignees across 198 records, and it is heavily front-loaded: the leading assignee alone holds 37 records, more than double the count at fifth place (14). The top five assignees combined hold 55.6% of all 198 records, and the top ten hold 85.4%. This means the vast majority of the remaining 56-plus ranked companies each hold only a small handful of filings, forming a long tail behind a small group of established filers.
Filing activity peaked in 2018 at 35 records and cooled in the years after, but the 2021-to-2024 window — the last period not distorted by publication lag — shows a +50% increase, from 2 to 3 records. Because publication typically lags actual filing by around 18 months, the years closest to the 2026 data cut-off will understate real activity and should not be read as a decline. The underlying trend is one of renewed, if modest, growth rather than an exit from the category.
Sterilising and disinfecting functionality (IPC class A61L) is by far the most claimed area, appearing in 78.3% of the 198 records in scope. Implant and prosthesis-related claims (A61F) and medicinal preparation claims (A61K) each appear in roughly a third of records, at 31.8% and 31.3% respectively. Claims specific to the polysaccharide chemistry itself, under C08B, appear in only 8.6% of records, indicating that most patent activity protects the dressing's clinical function rather than the base polymer science.
The lowest-density IPC classes in this dataset — C08B (polysaccharides and derivatives) at 8.6% and C08J (polymer processing and solutions) at 9.1% — sit well below the dominant sterilising and implant classes, suggesting these branches are comparatively under-claimed. Diagnosis-integrated surgical applications under A61B also sit low at 7.1% of records. A first claim in these areas would likely focus on novel processing routes, deacetylation control, or diagnostic-integrated hemostat formats rather than another sterilising-function claim.
US20210052766A1, assigned to Tricol Biomedical, Inc. and published 2021-02-25, covers a biocompatible, foldable, thin-profile, low-mass, high-surface-area chitosan dressing optionally modified with catechol, intended for treating bleeding including gastrointestinal bleeding. It is a representative rather than the most-cited filing in this landscape, so its blocking scope should be assessed against the specific structural and catechol-modification claims rather than assumed to cover all chitosan dressings. Teams working on structurally similar thin-profile chitosan formats should review its claim language directly before finalizing a competing design.
Research Chitosan and Polysaccharide Hemostats in depth with Eureka
Go past this page: query the whole chitosan and polysaccharide hemostats corpus yourself, in your own scope.
Every answer comes back with patent numbers you can open.
Disclaimer. This page is generated from Patsnap Eureka data drawn from a limited snapshot of global patent and scientific-literature records, and is provided for general information and reference only.
Patent data carries inherent limitations: recent filings (typically the most recent 18–24 months) are under-counted due to standard publication lag; counts may be reported at either a patent-family or a patent-record basis and are not always directly comparable; classification, applicant-name, and citation data may contain errors, duplicates, or omissions; and the underlying search query defines and constrains the scope shown. As a result, the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing on this page constitutes an exhaustive prior-art, novelty, freedom-to-operate, or validity search, nor does it constitute legal, financial, investment, or professional advice, and it should not be relied upon as such. Any patent, commercial, or strategic decision should be verified independently and reviewed with qualified patent, legal, and domain professionals. Patsnap makes no warranties, express or implied, as to the accuracy, completeness, or fitness for any particular purpose of the information presented.
Machine translation. Assignee and organisation names originally recorded in Chinese, Japanese or Korean have been rendered into English by an AI translation step so that the tables stay readable. These renderings are best-effort and may not match a company’s registered English name; the original name is what the underlying patent record carries, and it is what any Eureka query launched from this page uses.